Lutathera supports improved survival for patients with neuroendocrine tumors

By Brian Buntz | July 21, 2021

lutathera Novartis somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors Novartis’ Lutathera, a drug indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, including foregut, midgut, and hindgut tumors, was recently highlighted at the World Congress on Gastrointestinal Cancer 2021. Dr. Jonathan R. Strosberg, head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Fla., presented positive survival data from the Phase 3 NETTER-1 trial.

The study demonstrated that Lutathera significantly improved survival outcomes in patients with midgut neuroendocrine tumors. Specifically, the drug extended survival by 11.7 months compared to the control group. These findings underscore the potential of Lutathera as an effective treatment option for patients with this type of cancer.

Filed Under: Oncology
Tagged With: Lutathera, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, tumors

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].